Multiple Myeloma and Acute Kidney Injury: Mechanisms Involved
Main Article Content
Abstract
The renal manifestations of multiple myeloma are devastating coupled with a disease as aggressive as the aforementioned. Its pathophysiological understanding has been clarified over time and has revealed the different mechanisms by which difficult-to-manage kidney damage occurs. However, the different therapies that have been developed have made this disease have an increasingly better prognosis. It is still a therapeutic challenge to treat myeloma together with a disease as complex as kidney disease.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Gödecke V, Schmidt JJ, Bräsen JH, Koenecke C, Haller H. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies]. Internist (Berl). 2019 Jan;60(1):10-22
II. Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011 Sep;6(9):2165-74.
III. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, Herrera GA, Lachmann H, Sanders PW., International Kidney and Monoclonal Gammopathy Research Group. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011 Nov 01;8(1):43-51.
IV. Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001 Sep;56(3):207-10
V. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA., Greek Myeloma Study Group. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007 Feb;48(2):337-41.
VI. Herrera GA, Sanders PW. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib Nephrol. 2007;153:105-15.
VII. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004 Aug;128(8):875-9.
VIII. Daidola G, Guarena C, Brustia M, Leonardi G, Vigotti FN, Marciello A, Bianco S, Chiarinotti D, Saltarelli M, Besso L, Biancone L. [Efficacy of SUPRA HFR in the treatment of acute renal damage during multiple myeloma]. G Ital Nefrol. 2018 Dec;35(6)
IX. Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990 Feb;85(2):570-6.
X. Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. J Natl Cancer Inst. 2019 Jul 01;111(7):727-736.
XI. Huskey JL, Heilman RL, Khamash H, Fonseca R. Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. Transplantation.
XII. Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion. 2007 Mar;47(3):511-4.
XIII. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun;73(11):1282-8.
XIV. Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, Pedrosa I. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol. 2011 May;196(5):1094-101
XV. Chinese Hematology Association; Chinese Society of Hematology; Chinese Myeloma Committee-Chinese Hematology Association. [The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].
XVI. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002 Sep;48(9):1437-44.